The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation
Yıl: 2020 Cilt: 57 Sayı: 3 Sayfa Aralığı: 204 - 209 Metin Dili: İngilizce DOI: 10.29399/npa.23363 İndeks Tarihi: 05-11-2020
The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation
Öz: Introduction: The overproduction of the efflux transporters in the bloodbrainbarrier is considered to play a role in the development of drugresistance in mesial temporal lobe epilepsy (MTLE) patients. The aim ofthe present study was to investigate the relationship of clinical features ofpatients with MTLE accompanied by hippocampal sclerosis (HS) and thep-glycoprotein (p-gp) expression and neuronal loss in the hippocampus.Methods: This study included a total of 33 patients who underwentselective amygdala-hippocampectomy operation. A detailed medicalhistory of each patient, including age, side of HS, sex, age of habitualseizure onset, duration of habitual seizures, type and age of initialprecipitating injury, presence and duration of latent period, presenceand duration of silent period, monthly seizure frequency within 1 yearprior to operation, mean age at the time of operation was evaluatedretrospectively.Results: The p-gp expression was significantly higher in the patient groupwith a seizure frequency of more than 15 days per month and a diseaseduration of more than 20 years. There was no significant differencebetween the p-gp expression and the clinical features of the MTLE-HSpatients.Conclusion: These results suggest that p-gp expression is affected bydisease duration and seizure frequency rather than a patient’s clinicaland pathological properties. In patients with HS-MTLE, potential use ofthe p-gp inhibitors as additional therapy and developing novel drugs notcarried by multidrug carriers expressed in blood-brain barrier should beregarded as the new treatment targets.
Anahtar Kelime: Selektif Amigdalohipokampektomi Operasyonu Geçiren Mezial Temporal Lob Epilepsili Hastaların Klinik-Patolojik Özellikleri ile Hipokampal Sklerozda p-Glikoprotein Ekspresyonu İlişkisi
Öz: Amaç: Kan beyin bariyerinde “efflux transporter”ların aşırı üretiminin mezial temporal lob epilepsili (MTLE) hastalarda ilaç tedavisine direnç gelişiminde rol oynayabileceği düşünülmektedir. Bu çalışmada, hipokampal sklerozun (HS) eşlik ettiği MTLE’li hastaların klinik özellikleri ile hipokampusta p-glikoprotein (p-gp) ekspresyonu ve nöronal kayıp arasındaki ilişkiyi araştırmak amaçlanmaktadır. Yöntem: Selektif amigdala-hipokampektomi operasyonu geçirmiş 33 hasta çalışmaya alındı. Her hastanın yaş, HS’nin bulunduğu taraf, cinsiyet, habitüel nöbetlerin başladığı yaş, habitüel nöbetlerin süresi, IPI’nin tipi ve geliştiği yaş, “latent period” varlığı ve süresi, “silent period” varlığı ve süresi, operasyon öncesindeki bir yıl içinde aylık ortalama nöbet frekansı ve operasyonun yapıldığı yaşın ortalaması içeren ayrıntılı klinik hikâyesi retrospektif olarak incelendi. Bulgular: P-gp ekspresyonu ayda 15 günden fazla nöbet sıklığı ve 20 yıldan fazla hastalık süresi olan hasta grubunda anlamlı olarak daha fazla idi. MTLE-HS hastalarının klinik özellikleri ve p-gp ekspresyonu arasında anlamlı bir fark yoktu. Sonuç: Bu bulgular p-gp ekspresyonunun hastanın klinik ve patolojik özelliklerinden çok hastalığın süresi ve nöbet sıklığından etkilendiğini düşündürmektedir. HS-MTLE hastalarında, inhibitörlerin ek tedavi olarak olası kullanımı ve kan beyin bariyerinde eksprese edilen “multi-drug” taşıyıcıları ile taşınmayan ilaçların geliştirilmesi yeni tedavi hedefleri olarak değerlendirilmelidir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Bianchin MM, Velasco TR, Wichert-Ana L, Dos Santos AC, Sakamoto AC. Understanding the association of neurocysticercosis and mesial temporal lobe epilepsy and its impact on the surgical treatment of patients with drugresistant epilepsy. Epilepsy Behav 2017;76:168–177. [CrossRef]
- 2. Kim WJ, Park SC, Lee SJ, Lee JH, Kim JY, Lee BI, Kim DI. The prognosis for control of seizures with medications in patients with MRI evidence for mesial temporal sclerosis. Epilepsia 1999;40:290–293. [CrossRef]
- 3. Malmgren K, Thom M. Hippocampal sclerosis-origins and imaging. Epilepsia 2012;53(Suppl 4):19–33. [CrossRef]
- 4. Wieser HG; ILAE Commission on Neurosurgery of Epilepsy. ILAE Commision Report, Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis. Epilepsia 2004;45:695–714. [CrossRef]
- 5. Arzimanoglou A, Aldenkamp A, Cross H, Lassonde M, Moshé S, Schmitz B. Cognitive dysfunction in children with temporal lobe epilepsy. Paris; John Libbey Eurotext; 2005.
- 6. Mathern GW, Pretorius JK, Babb TL. Influence of the type of initial precipitating injury and at what age it occurs on course and outcome in patients with temporal lobe seizures. J Neurosurg 1995;82:220–227. [CrossRef]
- 7. Spector R. Drug Transport in the mammalian central nervous system: multiple complex systems. A critical analysis and commentary. Pharmacology 2000;60:58–73. [CrossRef]
- 8. Abbott NJ, Khan EU, Rollinson CMS, Reichel A, Janigro D, Dombrowski SM, Dobbie MS, Begley DJ. Drug resistance in epilepsy: the role of the bloodbrain barrier. In: Ling V, editor. Mechanisms of drug resistance in epilepsy. Lessons from Oncology. Chichester: Wiley, Ltd.; 2002. pp.38–47.
- 9. Weidner LD, Kannan P, Mitsios N, Kang SJ, Hall MD, Theodore WH, Innis RB, Mulder J. The expression of inflammatory markers and their potential influence on efflux transporters in drug-resistant mesial temporal lobe epilepsy tissue. Epilepsia 2018;59:1507–1517. [CrossRef]
- 10. Kubota H, Ishihara H, Langmann T, Schmitz G, Stieger B, Wieser HG, Yonekawa Y, Frei K. Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res 2006;68:213–228. [CrossRef]
- 11. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med 2011;365:919–926. [CrossRef]
- 12. Wyler AR, Dohan FC, Schweitzer JB, Berry AD. A Grading System for Mesial Temporal Pathology (Hippocampal Sclerosis) from Anterior Temporal Lobectomy. J Epilepsy 1992;5:220–225. [CrossRef]
- 13. Mathern GW, Babb TL, Leite JP, Pretorius K, Yeoman KM, Kuhlman PA. The Pathogenic and progressive features of chronic human hippocampal epilepsy. Epilepsy Res 1996;26:151–161. [CrossRef]
- 14. Blümcke I, Pauli E, Clusmann H, Schramm J, Becker A, Elger C, Merschhemke M, Meencke HJ, Lehmann T, von Deimling A, Scheiwe C, Zentner J, Volk B, Romstöck J, Stefan H, Hildebrandt M. A new clinico-pathological classification system for mesial temporal sclerosis. Acta Neuropathol 2007;113:235–244. [CrossRef]
- 15. Davies KG, Hermann BP, Dohan Jr FC, Foley KT, Bush AJ, Wyler AR. Relationship of hippocampal sclerosis to duration and age of onset of epilepsy, and childhood febrile seizures in temporal lobectomy patients. Epilepsy Res 1996;24:119–126. [CrossRef]
- 16. Sagar HJ, Oxbury JM. Hippocampal neuron loss in temporal lobe epilepsy: correlation with early childhood convulsions. Ann Neurol 1987;22:334–340. [CrossRef]
- 17. Berg AT, Langfitt J, Shinnar S, Vickrey BG, Sperling MR, Walczak T, Bazil C, Pacia SV, Spencer SS. How long does it take for partial epilepsy to become intractable? Neurology 2003;60:186–190. [CrossRef]
- 18. Löscher W, Potschka H. Blood-brain barrier Active Efflux Transporters: ATPBinding Cassette Gene Family. Neuro Rx 2005;2;86–98. [CrossRef]
- 19. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common cause of refractory epilepsy. Brain 2002;125:22–31. [CrossRef]
- 20. Aronica E, Gorter JA, Ramkema M, Redeker S, Ozbas-Gerçeker F, van Vliet EA, Scheffer GL, Scheper RJ, van der Valk P, Baayen JC, Troost D. Expression and cellular distribution of multidrug resistance -related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 2004;45:441–451. [CrossRef]
- 21. Löscher W, Potschka H. Role of multidrug transporter in the pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002;301:7– 14. [CrossRef]
- 22. Potschka H, Löscher W. In vivo evidence for Pglycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 2001;42:1231–1240. [CrossRef]
- 23. van Vliet EA, van Schaik R, Edelbroek PM, Redeker S, Aronica E, Wadman WJ, Marchi N, Vezzani A, Gorter JA. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 2006;47:672–680. [CrossRef]
- 24. Rizzi M, Guiso G, Mule F, Moneta D, Sperk G, Vezzani A, Caccia S. Induction of MDR-1 by limbic seizures in mice: relevance for drug resistance in epilepsy. Soc Neurosci Abstr 2001;27:553.2.
- 25. Liu JY, Thom M, Catarino CB, Martinian L, Figarella-Branger D, Bartolomei F, Koepp M, Sisodiya SM. Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain 2012;135:3115–3133. [CrossRef]
- 26. Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005;76:22–76. [CrossRef]
- 27. Aronica E, Gorter JA, Jansen GH, van Veelen CW, van Rijen PC, Leenstra S, Ramkema M, Scheffer GL, Scheper RJ, Troost D. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glianeurol tumors. Neuroscience 2003;118:417–429. [CrossRef]
- 28. Regesta G, Tanganelli P. Clinical aspects and biological bases of drug resistant epilepsies. Epilepsy Res 1999;34:109–122. [CrossRef]
- 29. Kwan P, Li HM, Al-Jufairi E, Abdulla R, Gonzales M, Kaye AH, Szoeke C, Ng HK, Wong KS, O’Brien TJ. Association between temporal lobe P-glycoprotein expression and seizure recurrence after surgery for pharmacoresistant temporal lobe epilepsy. Neurobiol Dis 2010;39:192–197. [CrossRef]
- 30. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit 2000;22:137–140. [CrossRef]
| APA | ETHEMOĞLU ö, Kayrak N, Bilgiç B, Gul G, Yandım Kuscu D, KIRBAŞ D (2020). The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation. , 204 - 209. 10.29399/npa.23363 |
| Chicago | ETHEMOĞLU özlem,Kayrak Nalan,Bilgiç Bilge,Gul Gunay,Yandım Kuscu Demet,KIRBAŞ DURSUN The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation. (2020): 204 - 209. 10.29399/npa.23363 |
| MLA | ETHEMOĞLU özlem,Kayrak Nalan,Bilgiç Bilge,Gul Gunay,Yandım Kuscu Demet,KIRBAŞ DURSUN The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation. , 2020, ss.204 - 209. 10.29399/npa.23363 |
| AMA | ETHEMOĞLU ö,Kayrak N,Bilgiç B,Gul G,Yandım Kuscu D,KIRBAŞ D The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation. . 2020; 204 - 209. 10.29399/npa.23363 |
| Vancouver | ETHEMOĞLU ö,Kayrak N,Bilgiç B,Gul G,Yandım Kuscu D,KIRBAŞ D The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation. . 2020; 204 - 209. 10.29399/npa.23363 |
| IEEE | ETHEMOĞLU ö,Kayrak N,Bilgiç B,Gul G,Yandım Kuscu D,KIRBAŞ D "The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation." , ss.204 - 209, 2020. 10.29399/npa.23363 |
| ISNAD | ETHEMOĞLU, özlem vd. "The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation". (2020), 204-209. https://doi.org/10.29399/npa.23363 |
| APA | ETHEMOĞLU ö, Kayrak N, Bilgiç B, Gul G, Yandım Kuscu D, KIRBAŞ D (2020). The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation. Nöropsikiyatri Arşivi, 57(3), 204 - 209. 10.29399/npa.23363 |
| Chicago | ETHEMOĞLU özlem,Kayrak Nalan,Bilgiç Bilge,Gul Gunay,Yandım Kuscu Demet,KIRBAŞ DURSUN The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation. Nöropsikiyatri Arşivi 57, no.3 (2020): 204 - 209. 10.29399/npa.23363 |
| MLA | ETHEMOĞLU özlem,Kayrak Nalan,Bilgiç Bilge,Gul Gunay,Yandım Kuscu Demet,KIRBAŞ DURSUN The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation. Nöropsikiyatri Arşivi, vol.57, no.3, 2020, ss.204 - 209. 10.29399/npa.23363 |
| AMA | ETHEMOĞLU ö,Kayrak N,Bilgiç B,Gul G,Yandım Kuscu D,KIRBAŞ D The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation. Nöropsikiyatri Arşivi. 2020; 57(3): 204 - 209. 10.29399/npa.23363 |
| Vancouver | ETHEMOĞLU ö,Kayrak N,Bilgiç B,Gul G,Yandım Kuscu D,KIRBAŞ D The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation. Nöropsikiyatri Arşivi. 2020; 57(3): 204 - 209. 10.29399/npa.23363 |
| IEEE | ETHEMOĞLU ö,Kayrak N,Bilgiç B,Gul G,Yandım Kuscu D,KIRBAŞ D "The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation." Nöropsikiyatri Arşivi, 57, ss.204 - 209, 2020. 10.29399/npa.23363 |
| ISNAD | ETHEMOĞLU, özlem vd. "The Relationship Between Clinico-Pathological Properties and p-Glycoprotein Expression in Hippocampal Sclerosis Among Patients with Mesial Temporal Lobe Epilepsy Who Undergo Selective Amygdalohippocampectomy Operation". Nöropsikiyatri Arşivi 57/3 (2020), 204-209. https://doi.org/10.29399/npa.23363 |
